Condition: Atopic Dermatitis · Sponsor: AbbVie
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib 15mg or dupilumab 300mg. Based on the participants response to upadacitinib 15mg, they may have their dose increased to upadacitinib 30mg after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 200 adult participants ages 18 to less than 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 130 sites worldwide. The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for …
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Cahaba Dermatology & Skin Health Center /ID# 263855 | Birmingham, Alabama, United States | Recruiting |
| One Of A Kind Clinical Research Center - Scottsdale /ID# 278675 | Scottsdale, Arizona, United States | Recruiting |
| Clinical Trials Institute - Northwest Arkansas /ID# 267290 | Fayetteville, Arkansas, United States | Recruiting |
| Exalt Clinical Research /ID# 281611 | Chula Vista, California, United States | Recruiting |
| Private Practice - Dr. Tooraj Raoof /ID# 263849 | Encino, California, United States | Recruiting |
| First OC Dermatology /ID# 263349 | Fountain Valley, California, United States | Recruiting |
| NorCal Medical Research /ID# 278397 | Greenbrae, California, United States | Recruiting |
| Allergy & Asthma Associates of Southern California - Mission Viejo /ID# 266574 | Mission Viejo, California, United States | Recruiting |
| Dermatologist Medical Group of North County- Profound Research /ID# 266512 | Oceanside, California, United States | Recruiting |
| Comprehensive Dermatology Center of Pasadena /ID# 281014 | Pasadena, California, United States | Recruiting |
| Stanford University School of Medicine - Redwood City /ID# 263776 | Redwood City, California, United States | Recruiting |
| Integrative Skin Science and Research /ID# 264537 | Sacramento, California, United States | Recruiting |
+ 116 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06389136